TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* Metastatic melanoma with activating V600 BRAF mutation~* Measurable Tumor~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1~Exclusion Criteria:~* Autoimmune disease~* Active Brain Metastasis (must be stable after radiation for at least one month)~* Prior therapy with immune stimulating agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ipilimumab + Vemurafenib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained~* DSM-IV diagnosis must be one of:~  * schizophrenia~ * schizophreniform~ * schizoaffective~ * delusional disorder~ * brief reactive psychosis~ * psychosis not otherwise specified~* Ethnic origin of both parents must be known~* A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses~* Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment)~Exclusion criteria:~* Significant psychiatric or medical co-morbidity including history of:~  * head injury with loss of consciousness~ * seizures~ * neurological disorder~ * mental retardation (DSM-IV)~ * drug or alcohol dependence (DSM-IV)~ * serious physical illness e.g. malignancy, hepatic/renal insufficiency~* Concomitant psychotropic medication that may influence ratings~* Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for \>2 weeks during the antipsychotic treatment period rated

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: None): Subjects treated with olanzapine as part of their routine clinical care
- Risperidone (Type: None): Subjects treated with risperidone as part of their routine clinical care
- Quetiapine (Type: None): Subjects treated with quetiapine as part of their routine clinical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptoms suspicious of bladder cancer (haematuria, ultrasonic and cystoscopy findings)~* Chronic spinal cord injury for a minimum of 3 years~* Informed Consent as documented by signature~Exclusion Criteria:~* Age \< 18 years~* History of bleeding disorder~* Bladder augmentation~* Acute, symptomatic urinary tract infection~* Pregnancy~* Urolithiasis~* Previous intravesical treatment (e.g. bladder irrigation, botulinum toxin injection) \< 2 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- progressive or metastatic non-small cell lung cancer that diagnosed Pathologically or cytologically diagnosed patients who have received EGFR tyrosine kinase inhibitor monotherapy (e.g., gefetinib, erlotinib, ecotinib, afatinib) for disease progression EGFR T790M mutation was confirmed ECOG PS≤1 Adequate blood cell counts, kidney function and liver function Patients should participate in the study voluntarily and sign informed consent~Exclusion Criteria:~Patients with non-small-cell lung cancer who have received osimertinib or other raw materials or preparations for EGFRT790M mutant drugs Hypertension (systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication; Hepatitis B virus patients with active replication (DNA\> 500 cps / mL), hepatitis C; Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TQB3456 (Type: EXPERIMENTAL): p.o. qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Houston Independent School District (HISD) Yoga Evaluation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Fourth and Fifth graders in Houston Independent School District (HISD) schools that are participating in the Sonima Foundation's Health and Wellness Program~2. Participant on USD study protocol.~Exclusion Criteria: 1)~1. Participants who are taking any antipsychotic medications~2. Participants with active central nervous system (CNS) disease or encephalopathy~3. Participants who have ever been diagnosed with bipolar disorder or schizophrenia~4. Participants who have a history of head injury or who have a known seizure activity.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- Electroencephalograph (EEG) + Testing (Type: EXPERIMENTAL): Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib in Treating Patients With Early-Stage Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of primary adenocarcinoma of the rectum (to be histologically confirmed upon study entry)~  * Tumor must be at or below the peritoneal reflection~ * The distal border of the tumor is within 12 cm of the anal verge on proctoscopic examination~* Clinically resectable disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* WBC ≥ 4,000/mm³~* Platelet count ≥ 150,000/mm³~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other serious medical illness (other than rectal cancer) that would preclude study therapy~* No psychiatric condition that would preclude informed consent~* No history of allergy to celecoxib or any other NSAIDs, including acetylsalicylic acid (i.e., aspirin), ibuprofen, or indomethacin~* No history of allergy to sulfonamides~Exclusion criteria:~Not noted~PRIOR CONCURRENT THERAPY:~* At least 7 days since prior and no concurrent NSAIDs or other cyclooxygenase-2 inhibitors~* No concurrent warfarin, except low-dose warfarin (i.e., 1 mg/day) administered for prophylaxis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic Intervention/Celecoxib (Type: EXPERIMENTAL): Celecoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission within 48 hours for acute decompensated heart failure with at least one symptom and one sign of volume overload~* Receipt of loop diuretic prior to admission~* Plan to administer furosemide 120 - 160 mg IV bolus twice daily over the next 24 hours with additional diuresis deemed necessary~* If patient is concurrently administered intravenous vasodilator or inotrope, the dose of vasodilator or inotrope must be stable for 6 hours prior to enrollment with a plan to continue the same dose for the 24 hour duration of this study~Exclusion Criteria:~* Metolazone prescribed prior to admission~* Receipt of continuous intravenous infusion of furosemide~* Cirrhosis or end stage renal disease~* Non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Metolazone Pre-dosing (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
- Metolazone Concurrent Dosing (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Geographic Atrophy Treatment Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to give written informed consent, make required study visits, and follow instructions.~* Able to administer eye drops or have a caretaker to administer the eye drops.~* Study eye: Atrophy secondary to age-related macular degeneration, best corrected visual acuity (BCVA) of 35 letters (20/200 Snellen equivalent) or better, clear ocular media, and adequate pupillary dilation.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Pregnant, nursing, or not using adequate contraception.~* Ocular disease in the study eye, other than non-exudative AMD.~* History of cataract surgery in either eye within the past 3 months of screening.~* History or evidence of serious ocular trauma or intraocular surgery in either eye within the past 6 months of screening.~* Any medical condition that would make participation in the trial or adherence to the study schedule difficult or unlikely.~* Participation in an investigational drug or device study within 30 days of screening.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AL-8309B 1.0% (Type: EXPERIMENTAL): AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
- AL-8309B 1.75% (Type: EXPERIMENTAL): AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
- Vehicle (Type: PLACEBO_COMPARATOR): AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older at the time of enrollment.~* Postpartum period \< 42 days at the time of enrollment.~* Sufficient venous access to permit administration of study medication.~* 2 clinical signs of postpartum endometritis:~  * Oral body temperature of \> 101oF at any time, or a temperature of 100.4 on two occasions 6 hours apart.~ * Maternal tachycardia that parallels the temperature.~ * Uterine tenderness~ * Purulent vaginal discharge~* Findings of advanced endometritis: dynamic ileus, pelvic peritonitis, pelvic abscess, bowel obstruction, necrosis of the lower uterine segment.~Exclusion Criteria:~* History of previous hypersensitivity reactions to beta lactams.~* Receiving valproic acid or divalproex sodium.~* Creatinine clearance \< 30 mL/min as calculated by the Cockroft-Gault equation.~* Subject with a medical condition that, in the opinion of the investigator, would interfere with the pharmacokinetic evaluation of the medication, place the subject at an unacceptable risk of injury, or render the subject unable to meet the requirements of the protocol.~* Previous participation in the study.~* Exposure to ertapenem in the week prior to the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ertapenem (Type: EXPERIMENTAL): Women diagnosed with postpartum endometritis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Body weight \>/= 99lbs~* ECOG 0-2~* Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy~* Screening hemoglobin level of \</= 11.0 g/dL for men or \</= 10.0 for women~Exclusion Criteria:~* History of or concurrent second malignancy~* Evidence of primary or metastatic malignancy involving the Central Nervous System

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with secondary Raynaud's phenomenon suffering from severe Raynaud-'s phenomenon with trophical changes or from digital ulcers with written informed consent. Patients had to be stable for their systemic disease and were on stable medication concerning immunosuppression or vasoactive therapies for three months.~Exclusion Criteria:~* Current smokers, patients with a history of gastric ulcers in the last three months, a cardiac ejection fraction below 25%, patients with severe organ involvement or other uncontrolled diseases such as instable angina pectoris, severe anaemia, coagulopathies, azothaemia, cerebral stroke in the last 6 months or malignant diseases were excluded from the study. The last iloprost therapy had to be finished at least 6 months ago. Participation in other studies during the last 4 weeks was also not allowed. For fertile women, a negative pregnancy test was required.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): low dose iloprost therapy 0.5 ng/kg x min
- B (Type: ACTIVE_COMPARATOR): high-dose therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin and Enoxaparin for VTE in Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Blunt or penetrating trauma~* Requires VTE thromboprophylaxis~* High-risk for VTE~Exclusion Criteria:~* Presence of VTE upon admission~* Pregnant or nursing~* Inability to give informed consent by patient or healthcare proxy~* Contraindication to enoxaparin~* Contraindication to aspirin~* Epidural or subdural hematoma~* Presence, or removal within the last 12 hours, of an epidural or spinal catheter, or recent (within the last 12 hours) epidural or spinal anesthesia/procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Molecular Weight Heparin (LMWH) + Aspirin (ASA) (Type: EXPERIMENTAL): Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
- Low Molecular Weight Heparin (LMWH) Alone (Type: ACTIVE_COMPARATOR): Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Transfusion of Older Stored Red Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria (Recipient):~* specific, well-characterized hemoglobinopathy~* chronic simple transfusion therapy (transfusion episodes \< 6 weeks apart in frequency)~* chronic iron chelation therapy~* not pregnant by self-report and not planning pregnancy~* age \> 1 year old~Exclusion Criteria (Recipient):~* clinically unstable~* treatment for mental illness~* imprisonment~* institutionalization~Inclusion Criteria (Donor):~* 21-65 years of age~* male weight \> 130 lbs, female weight \> 150 lbs~* male height \> 5'1, female height \> 5'5~* hemoglobin \> 15.0 g/dL~* reasonably certain of intention to stay in New York City metropolitan area for study duration~* previously tolerated red blood cell donation~Exclusion Criteria (Donor):~* ineligible for donation based on New York Blood Center blood donor screening questionnaire~* systolic blood pressure \< 90 or \> 180 mm Hg, diastolic blood pressure \< 50 or \> 100 mm Hg~* heart rate \< 50 or \> 100~* temperature \> 99.5 F prior to donation~* positive by standard infectious disease testing performed on blood donors

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Transfusion of Fresh blood (Type: ACTIVE_COMPARATOR): The recipient will receive one or two units of fresh blood \<14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
- Transfusion of Stored blood (Type: EXPERIMENTAL): The recipient will receive one or two units of old blood \>28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
- Transfusion of Cryopreserved Blood (Type: ACTIVE_COMPARATOR): The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
- Transfusion of Washed Blood (Type: ACTIVE_COMPARATOR): The recipient will receive one or two units of washed (fresh/old) stored blood \>28 days old, as per their chronic transfusion schedule - off chelation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues